{"id":"chloroquine-primaquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hemolytic anemia (in G6PD-deficient patients)"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chloroquine accumulates in the parasite's food vacuole and inhibits heme polymerization, leading to toxic heme accumulation and parasite death. Primaquine is a prodrug that generates reactive metabolites targeting the parasite's mitochondria and is particularly effective against hypnozoites (dormant liver stages), preventing relapse. Together they provide both acute and causal prophylaxis against malaria.","oneSentence":"Chloroquine and primaquine work together as antimalarial agents by interfering with parasite DNA and disrupting the parasite's ability to metabolize hemoglobin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:01.945Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria treatment and prevention"},{"name":"Plasmodium vivax and Plasmodium ovale malaria (including hypnozoite eradication)"}]},"trialDetails":[{"nctId":"NCT06923592","phase":"PHASE3","title":"Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar","status":"RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2025-05-12","conditions":"Malaria Vivax, Malaria Falciparum, Plasmodium Vivax","enrollment":19200},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":"Plasmodium Vivax Malaria, Malaria","enrollment":7530},{"nctId":"NCT06666491","phase":"PHASE3","title":"An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Malaria, Vivax","enrollment":300},{"nctId":"NCT05540470","phase":"NA","title":"Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield","status":"COMPLETED","sponsor":"Centre Hospitalier de Cayenne","startDate":"2022-09-12","conditions":"Malaria, Vivax","enrollment":1991},{"nctId":"NCT03529396","phase":"PHASE2","title":"Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients","status":"COMPLETED","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2018-07-20","conditions":"Vivax Malaria, G6PD Deficiency","enrollment":106},{"nctId":"NCT04079621","phase":"PHASE4","title":"Short Course Radical Cure of P. Vivax Malaria in Nepal","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2021-10-27","conditions":"Malaria, Malaria, Vivax, Malaria,Falciparum","enrollment":27},{"nctId":"NCT02389374","phase":"PHASE4","title":"A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2014-08","conditions":"Malaria","enrollment":181},{"nctId":"NCT05753150","phase":"","title":"Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand","status":"COMPLETED","sponsor":"Dr. Prayuth Sudathip","startDate":"2022-05-23","conditions":"Malaria, Vivax, G6PD Deficiency","enrollment":187},{"nctId":"NCT06044805","phase":"PHASE4","title":"Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax","status":"COMPLETED","sponsor":"Dinka Dugassa","startDate":"2022-12-19","conditions":"Efficacy, Malaria, Chloroquine","enrollment":100},{"nctId":"NCT05958797","phase":"","title":"TES of Chloroquine for Pv in the Philippines in 2016","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2016-01-04","conditions":"Malaria, Vivax Malaria, Recrudescence","enrollment":74},{"nctId":"NCT04222088","phase":"","title":"TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2013-05-01","conditions":"Malaria, Falciparum Malaria, Vivax Malaria","enrollment":159},{"nctId":"NCT03208907","phase":"PHASE3","title":"DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil","status":"COMPLETED","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2018-07-05","conditions":"Malaria, Vivax, Therapeutics","enrollment":419},{"nctId":"NCT05232227","phase":"PHASE2, PHASE3","title":"Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2023-01-20","conditions":"Malaria, Vivax, Relapse","enrollment":""},{"nctId":"NCT05052502","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-11-01","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":49118},{"nctId":"NCT04368910","phase":"PHASE3","title":"Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria","status":"TERMINATED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09-06","conditions":"Malaria","enrollment":30},{"nctId":"NCT03337152","phase":"PHASE4","title":"Assessing a Risk Model for G6PD Deficiency","status":"TERMINATED","sponsor":"PATH","startDate":"2018-05-07","conditions":"Malaria, Vivax, G6PD Deficiency","enrollment":54},{"nctId":"NCT03610399","phase":"NA","title":"Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-04-09","conditions":"P Vivax, Malaria, Vivax","enrollment":257},{"nctId":"NCT04349410","phase":"PHASE2, PHASE3","title":"The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","status":"COMPLETED","sponsor":"The Camelot Foundation","startDate":"2020-04-11","conditions":"CoVid 19 Positive","enrollment":1800},{"nctId":"NCT02876549","phase":"PHASE4","title":"G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-09-01","conditions":"Vivax Malaria","enrollment":1000},{"nctId":"NCT04241705","phase":"NA","title":"Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia","status":"UNKNOWN","sponsor":"Armauer Hansen Research Institute, Ethiopia","startDate":"2020-01-20","conditions":"Malaria","enrollment":48960},{"nctId":"NCT01178021","phase":"PHASE4","title":"Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-08","conditions":"Vivax Malaria","enrollment":593},{"nctId":"NCT02216123","phase":"PHASE3","title":"Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-30","conditions":"Malaria, Vivax","enrollment":251},{"nctId":"NCT01376167","phase":"PHASE2","title":"Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-24","conditions":"Malaria, Vivax","enrollment":851},{"nctId":"NCT01290601","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults","status":"TERMINATED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2003-09-15","conditions":"Malaria, Plasmodium Vivax","enrollment":70},{"nctId":"NCT02043652","phase":"NA","title":"Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-02","conditions":"Malaria","enrollment":119},{"nctId":"NCT01205178","phase":"PHASE1","title":"G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-02","conditions":"Malaria","enrollment":192},{"nctId":"NCT02348788","phase":"PHASE3","title":"Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia","status":"UNKNOWN","sponsor":"Menzies School of Health Research","startDate":"2015-01","conditions":"Plasmodium Vivax Malaria Without Complication","enrollment":98},{"nctId":"NCT01680406","phase":"PHASE4","title":"Ethiopia Antimalarial in Vivo Efficacy Study 2012","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-10","conditions":"Plasmodium Vivax Infection","enrollment":398},{"nctId":"NCT00158548","phase":"PHASE3","title":"ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2001-06","conditions":"Malaria, Falciparum Malaria, Vivax Malaria","enrollment":650},{"nctId":"NCT01716260","phase":"","title":"Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2013-01","conditions":"Vivax Malaria","enrollment":24},{"nctId":"NCT01640574","phase":"PHASE3","title":"Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-02","conditions":"Vivax Malaria","enrollment":680},{"nctId":"NCT02691910","phase":"PHASE2, PHASE3","title":"Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2014-08","conditions":"Malaria, Vivax","enrollment":204},{"nctId":"NCT01708876","phase":"PHASE3","title":"P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2012-10","conditions":"Uncomplicated Plasmodium Knowlesi Malaria","enrollment":250},{"nctId":"NCT02394197","phase":"PHASE4","title":"Effectiveness of Malaria Treatment in Mexico","status":"COMPLETED","sponsor":"LILIA GONZALEZ CERON","startDate":"2008-02","conditions":"Malaria","enrollment":153},{"nctId":"NCT02143934","phase":"PHASE4","title":"Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity","status":"COMPLETED","sponsor":"Papua New Guinea Institute of Medical Research","startDate":"2009-08","conditions":"Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode, Plasmodium Falciparum Infection","enrollment":524},{"nctId":"NCT01784315","phase":"","title":"Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria","status":"UNKNOWN","sponsor":"Ministry of Health, Bhutan","startDate":"2013-03","conditions":"Parasitemia","enrollment":50},{"nctId":"NCT01074905","phase":"PHASE3","title":"Study on the Treatment of Vivax Malaria","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-05","conditions":"Vivax Malaria","enrollment":655},{"nctId":"NCT01662700","phase":"PHASE4","title":"Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2012-10","conditions":"Acute Uncomplicated Malaria With P.Vivax Infection","enrollment":120},{"nctId":"NCT01500980","phase":"PHASE1","title":"Malaria Challenge in Healthy Volunteers","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2011-12","conditions":"Malaria","enrollment":36},{"nctId":"NCT01218932","phase":"PHASE1","title":"Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-10","conditions":"Vivax Malaria","enrollment":16},{"nctId":"NCT00959517","phase":"PHASE2","title":"Trial of Artesunate Combination Therapy in Pakistan","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2001-07","conditions":"Uncomplicated Falciparum Malaria","enrollment":588}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Chloroquine + Primaquine","genericName":"Chloroquine + Primaquine","companyName":"U.S. Army Medical Research and Development Command","companyId":"u-s-army-medical-research-and-development-command","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chloroquine and primaquine work together as antimalarial agents by interfering with parasite DNA and disrupting the parasite's ability to metabolize hemoglobin. Used for Malaria treatment and prevention, Plasmodium vivax and Plasmodium ovale malaria (including hypnozoite eradication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}